绥美凯在国内上市了吗？

On January 20, 2018, GlaxoSmithKline China (GSK China) announced that its single-tablet compound preparation (chemical name: doptabalamid tablets) was officially launched in mainland China. This is the best-selling AIDS drug in the world in the past five years, and it is also an important part of GSK China in the field of AIDS in recent years. Since Suimeikan was approved for marketing in 2014, its sales have increased by leaps and bounds. In 2016, it ranked first in the global AIDS drug rankings, becoming the best-performing business segment of GSK. Regarding pricing, Suimeikai is currently priced at 2880$/month in the Chinese market. In an interview with an E-drug manager reporter, Xu Ding, vice president of government affairs and communications at GSK, said: Suimeike’s pricing in China is the lowest in neighboring countries and regions. Next, GSK will actively coordinate and communicate with relevant departments to promote Suimeike’s entry into China’s free AIDS drug list as soon as possible to benefit more patient groups.

Wu Hao, director of the Infection Center of You'an Hospital Affiliated to Capital Medical University, said in an interview with the E-drug manager that there are currently two mainstream directions in the global treatment of AIDS. One follows the European and American guidelines, and the other follows the World Health Organization guidelines (which are guidelines formulated by the WHO based on various factors such as the economy, resources, population income and other factors in underdeveloped areas). Currently, in the field of global AIDS treatment, DTG drugs are the only first-line drugs recommended by four guidelines (including IAS-USA, DHHS, EACS, and WHO). Since 1999, GSK has been approved for a total of eight HIV treatment drugs in China, and currently three products are on the national free catalog. Suimeikai, which is launched this time, is China's first complete single-piece three-in-one preparation with DTG as the core, filling the gap in single-piece compound preparations. GSK has previously had a DTG drug on the market, with the trade name Tevicay. It was launched in the United States in 2013, but it needs to be used in combination with other drugs. It is a complete single-piece three-in-one preparation with DTG as the core, one pill at a time, once a day, without considering factors such as food, environment, location, etc. AIDS is generally recognized as a chronic disease. "For chronic diseases, patient compliance is particularly important. Taking one pill once a day reduces the frequency and dosage of medication and significantly enhances patient compliance." Xu Ding added, "In the past, disease control focused more on the front end, but now more and more attention is paid to the back end. How patients use medications and their rational use also saves medical resources."